Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is overexpressed in 20–30% of breast cancers and is associated with poor prognosis and worse overall patient survival. Most women with HER2-positive breast cancer receive neoadjuvant chemotherapy plus HER2-targeted therapies. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Najjar, Mariana K., Manore, Sara G., Regua, Angelina T., Lo, Hui-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691220/
https://www.ncbi.nlm.nih.gov/pubmed/36360302
http://dx.doi.org/10.3390/genes13112065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691220/
https://www.ncbi.nlm.nih.gov/pubmed/36360302
http://dx.doi.org/10.3390/genes13112065

Ejemplares similares